Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial
Open Access
- 21 June 2021
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 46 (13) , 2250-2256
Abstract
Identification of new medications for alcohol use disorder (AUD) is important for improving treatment options. Baclofen, a GABABagonist, has been identified as a potential pharmacotherapy for AUD. In a 16-week double-blind, randomized, placebo-controlled trial, we investigated 30 and 90 mg/day of baclofen compared to placebo and examined effects of dose, sex, and level of pretreatment drinking. One hundred and twenty participants with DSM-IV alcohol dependence (age 46.1 (sd = 10.1) years, 51.7% male) were randomized after exclusion for unstable medical/psychiatric illness and/or dependence on drugs other than nicotine. Seventy-three participants completed the trial. A main effect of baclofen was found [%HDD (F(2,112) = 4.16,p = 0.018,d = 0.51 95%CI (0.06–0.95), 13.6 fewer HDD) and %ABST (F(2,112) = 3.68,p = 0.028,d = 0.49 95%CI (0.04–0.93), 12.9 more abstinent days)] and was driven by the 90 mg/day dose. A sex × dose interaction effect was present for both %HDD (F(2,110) = 5.48,p = 0.005) and %ABST (F(2,110) = 3.19,p = 0.045). Men showed a marginally positive effect for 90 mg/day compared to PBO (%HDD t(110) = 1.88,p = 0.063,d = 0.36 95%CI (−0.09–0.80), 15.8 fewer HDD days; %ABST t(110) = 1.68 (p = 0.096,d = 0.32 95%CI (−0.12–0.76), 15.7 more ABST)) with no effect for 30 mg/day. Women showed a positive effect for 30 mg/day (%HDD, t(110) = 3.19,p = 0.002,d = 0.61 95%CI (0.16–1.05), 26.3 fewer HDD days; %ABST t(110) = 2.73,p = 0.007,d = 0.52 95%CI (0.07–0.96), 25.4 more ABST days) with marginal effects for 90 mg/day on %ABST (p = 0.06) with drop-outs/dose reduction from sedative side-effects of 59% in women at 90 mg/day compared to 5% for men. These findings support the hypothesis that baclofen has efficacy in AUD and suggest that dose and sex be further explored as potential moderators of baclofen response and tolerability.Keywords
This publication has 38 references indexed in Scilit:
- Reduction of alcohol intake by the positive allosteric modulator of the GABAB receptor, rac-BHFF, in alcohol-preferring ratsAlcohol, 2013
- Suppression of Alcohol Dependence Using Baclofen: A 2-Year Observational Study of 100 PatientsFrontiers in Psychiatry, 2012
- Treating alcohol withdrawal with oral baclofen: A randomized, double‐blind, placebo‐controlled trialJournal of Hospital Medicine, 2011
- Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical TrialsAlcohol, Clinical and Experimental Research, 2010
- Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double‐Blind, Placebo‐Controlled TrialAlcohol, Clinical and Experimental Research, 2010
- Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled studyThe Lancet, 2007
- Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivationJournal of Psychiatric Research, 2006
- Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs DiazepamThe American Journal of Medicine, 2006
- Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐AnalysisAlcohol, Clinical and Experimental Research, 2001
- Application of random-effects pattern-mixture models for missing data in longitudinal studies.Psychological Methods, 1997